舒尼替尼治疗转移性肾癌的不良反应及处理  

Adverse Reactions and the Associated Countermeasures During the Treatment of Metastatic Renal Cell Carcinoma with Sunitinib

作　　者：许炯煊[1] 苏婧[1] 陈钦棋[1] 陈建德[1] 林超禄[1] 黄旭锋[1] 朱绍兴[2] 

机构地区：[1]福建医科大学附属龙岩市第一医院泌尿外科,福建龙岩364000 [2]浙江省肿瘤医院泌尿肿瘤外科,浙江杭州310022

出　　处：《中外医疗》2015年第35期17-19,共3页China & Foreign Medical Treatment

摘　　要：目的对舒尼替尼治疗晚期转移性肾癌的不良反应进行探讨,为临床用药提供参考。方法该院2011年9月—2015年1月共使用舒尼替尼治疗20例晚期转移性肾癌,分析患者的临床资料,观察治疗相关的不良反应并予以相应处理。结果最常见的不良反应为手足综合症9例(52.9%)、疲乏8例(47.1%)、白细胞减少、血小板减少各6例(35.3%)、药物性甲减7例(41.2%),约35.2%的患者出现3级及以上不良反应,2例予以药物减量治疗,3例因个人原因退出治疗。结论舒尼替尼治疗晚期转移性肾癌的不良反应多可耐受,安全性较好。Objective To summarize the adverse reactions of sunitinib in the treatment of advanced metastatic renal cell carcinoma so as to provide reference for the clinical medication. Methods A summary was conducted on the clinical data of 20 cases with advanced metastatic renal cell carcinoma admitted in our hospital from September 2011 to January 2015. The adverse reactions during treatment were observed and the associated countermeasures were given to the patients. Results The most common adverse reactions were hand-foot syndrome （9 cases）, accounting for 52.9%, fatigue （8 cases）, accounting for 47.1%, leucopenia（6 cases） and thrombocytopenia（6 cases）, accounting for 35.3%, drug-induced hypothyroidism（7 cases）, accounting for 41.2%. About 35.2% of the patients experienced grade 3 and above grade 3 adverse reactions, 2 cases de- creased the drug dose, 3 cases exited the treatment for personal reason. Conclusion Most of the adverse reactions of suni- tinib in the treatment of advanced metastatic renal cell carcinoma can be tolerated with good safety.

关 键 词：晚期转移性肾癌 舒尼替尼 靶向治疗 不良反应 

分 类 号：R4[医药卫生—临床医学]